Strategic niche Public utility pharmaceutical manufacturer focused on radioisotopes for diagnostic and therapeutic radiopharmaceuticals, with a specialized subsidiary (IRE ELiT) that develops radiopharmaceutical derivatives for cancer treatment and palliative care, indicating a targeted market segment and potential for high-value partnerships.

Regional footprint Based in Fleurus, Belgium, with activities including radiological monitoring across Belgian territory and international project development, suggesting opportunities for regional sales collaborations, lab services, and cross-border radiological analytics offerings.

Technical stack Utilizes a mix of traditional and modern technologies (PostgreSQL, Stimulus, Modernizr, SSH, Raspbian) indicating capability to integrate data-driven solutions, traceability systems, and secure remote collaboration tools to enhance manufacturing, QA, and supply chain processes.

Financial scale Revenue in the $1M–$10M range with 201–500 employees, signaling a mid-sized operation where targeted enterprise partnerships, contract manufacturing, and long-term supply agreements could yield meaningful growth with manageable risk.

Growth signals Active in radiological characterization, project development, and international collaboration through IRE ELiT, presenting multiple entry points for sales: radiochemical services, monitoring and analytics contracts, and radiopharmaceutical derivatives for oncology pipelines.